Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in mu...
Leadership
Robert J. Bitterman
President, CEO & Chairman
Lisa C. Carson
CFO, Principal Accounting Officer and VP of Finance & Administration
Linda M. Mahoney
Senior Vice President of Development
Jennifer Phillips Pharm.D.
Senior Vice President of Regulatory & Corporate Affairs
